Loading...
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients rec...
Na minha lista:
| Udgivet i: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5310702/ https://ncbi.nlm.nih.gov/pubmed/28210165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S94337 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|